Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1
Status:
Completed
Trial end date:
2010-06-25
Target enrollment:
Participant gender:
Summary
Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor
BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following
8 days of therapy in at least one dosing regimen that is safe and well tolerated in Clade B
HIV-1 infected subjects.